BBV87 is the Chikungunya vaccine candidate developed by Bharat Biotech. It is an inactivated whole virion vaccine made using a strain derived from an East, Central, South African (ECSA) genotype. The standard pre-clinical studies have found that it has an optimum immune response. As it is made using inactivated virion technology, it can be used by vulnerable populations such as immunocompromised individuals and pregnant women.
The International Vaccine Institute and Bharat Biotech announced the commencement of Phase II/III clinical trials of BBV87 in Costa Rica. Later, the trials will also begin in Panama and Colombia next month and in Thailand and Guatemala so after. The trial will assess the safety and immunogenicity of the vaccine candidate in healthy adults across the five countries where Chikungunya is endemic.